Palo Alto, CA – According to filings with the U.S. Securities and Exchange Commission, Kriya Therapeutics is raising $85,634,918.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Shankar Ramaswamy played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kriya Therapeutics

Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases.

To learn more about Kriya Therapeutics, visit http://kriyatherapeutics.com/

Contact:
Shankar Ramaswamy, Chief Executive Officer
833-574-9289
https://www.linkedin.com/in/shankar-ramaswamy-m-d-8334959/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved